Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy (ORCHARD) - ORCHARD

Study identifier:D6186C00001

ClinicalTrials.gov identifier:NCT03944772

EudraCT identifier:2018-003974-29

CTIS identifier:N/A

Recruitment Complete

Official Title

A biomarker-directed Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer whose Disease Has Progressed on First-Line Osimertinib Therapy.

Medical condition

Non-small Cell Lung Cancer

Phase

Phase 2

Healthy volunteers

No

Study drug

Osimertinib, Savolitinib, Gefitinib, Necitumumab, Durvalumab, Carboplatin, Pemetrexed, Alectinib, Selpercatinib, Selumetinib, Etoposide, Cisplatin, Datopotamab deruxtecan

Sex

All

Actual Enrollment

248

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 25 Jun 2019
Estimated Primary Completion Date: 06 May 2025
Estimated Study Completion Date: 06 May 2025

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jul 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria